Journal
ONCOTARGET
Volume 7, Issue 22, Pages 33306-33315Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.8949
Keywords
intraductal; radioimmunotherapy; trastuzumab; ductal carcinoma in situ; breast cancer
Categories
Funding
- SKCCC Core grant [P30 CA006973]
- NCI Breast SPORE [P50CA44473, R01 CA116477]
Ask authors/readers for more resources
The standard treatment for ductal carcinoma in situ (DCIS) of the breast is surgical resection, followed by radiation. Here, we tested localized therapy of DCIS in mice using the immunoconjugate Ac-225 linked-trastuzumab delivered through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu, while the alpha-emitter Ac-225 (half-life, 10 days) delivers highly cytotoxic, focused doses of radiation to tumors. Systemic Ac-225, however, elicits hematologic toxicity and at high doses free Bi-213, generated by its decay, causes renal toxicity. I.duc delivery of the radioimmunoconjugate could bypass its systemic toxicity. Bioluminescent imaging showed that the therapeutic efficacy of intraductal Ac-225-trastuzumab (10-40 nCi per mammary gland; 30-120 nCi per mouse) in a DCIS model of human SUM225 cancer cells in NSG mice was significantly higher (p<0.0003) than intravenous (120 nCi per mouse) administration, with no kidney toxicity or loss of body weight. Our findings suggest that i.duc radioimmunotherapy using Ac-225-trastuzumab deserves greater attention for future clinical development as a treatment modality for early breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available